Diamonds and Dogs
Teva Pharmaceutical Industries (TEVA) is making deals. Teva's stock is down over 50% in the last year, but the stock is up 5% today and up 30% in the last several weeks on news of a new CEO and deals to raise money. Teva is selling its Paragard intrauterine copper contraceptive to Cooper Co. for $1.1 billion in cash. Good news short term, but long term, the company still has $34 billion in debt to pare down.
Sage Therapeutics (SAGE) has seen better days. The biotech company said drug to treat a life-threatening seizure disorder failed to meet the main goal of a late-stage trial. The trial was testing Sage's drug, brexanolone, plus standard of care in patients with super-refractory status epilepticus (SRSE) whose seizures persisted despite earlier treatments, versus a placebo plus standard of care. The stock is down 17% to a three month low. The good news is the stock has rebounded from the morning lows already.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.